• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Mereo BioPharma Group plc (MREO)

American Depository Receipt
Sell: $2.00|Buy: $2.06|Change: 0 (0%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountSIPP

Company profile

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its tworare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Address

Fourth Floor
One Cavendish Place
London
GBR
W1G 0QF

Telephone

+44 3330237300

Website

https://www.mereobiopharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Mereo BioPharma Group PLC Second Quarter Earnings Results for 20262026-08-12T00:00:00
Mereo BioPharma Group PLC Annual General Meeting for 20262026-05-13T14:00:00
Mereo BioPharma Group PLC First Quarter Earnings Results for 20262026-05-13T00:00:00
Mereo BioPharma Group PLC Fourth Quarter Earnings Results for 20252026-03-26T00:00:00
Mereo BioPharma Group PLC Annual Report for 20252026-03-26T00:00:00
Mereo BioPharma Group PLC Third Quarter Earnings Results for 20252025-11-12T00:00:00

Previous key dates

NameKey Date
Cantor Global Healthcare Conference2025-09-04T08:35:00
Mereo BioPharma Group PLC Second Quarter Earnings Results for 20252025-08-12T00:00:00
Jefferies Global Healthcare Conference 20252025-06-04T16:20:00
Mereo BioPharma Group PLC Annual General Meeting for 20252025-05-13T14:00:00
Mereo BioPharma Group PLC First Quarter Earnings Results for 20252025-05-13T00:00:00
Mereo BioPharma Group PLC Fourth Quarter Earnings Results for 20242025-03-26T00:00:00
Mereo BioPharma Group PLC Annual Report for 20242025-03-26T00:00:00
Leerink Partners Global Healthcare Conference2025-03-12T08:40:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-16T08:15:00
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference2024-11-19T10:30:00
Mereo BioPharma Group PLC Third Quarter Earnings Results for 20242024-11-12T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.